{"doi":"10.1016/j.bict.2025.100020","title":"Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort","abstract":null,"journal":"Blood Immunology &amp; Cellular Therapy","year":2025,"id":608557,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1374804,"name":"Mark R. Dowling","orcid":"0000-0002-8056-5348","position":1,"is_corresponding":false},{"id":252356,"name":"Sara Vogrin","orcid":"0000-0002-1597-9421","position":2,"is_corresponding":false},{"id":237221,"name":"Olivia Smibert","orcid":"0000-0003-1232-5884","position":3,"is_corresponding":false},{"id":993220,"name":"Benjamin W. Teh","orcid":"0000-0003-0213-5470","position":4,"is_corresponding":false},{"id":1060428,"name":"Mary Ann Anderson","orcid":"0000-0002-3515-0215","position":5,"is_corresponding":false},{"id":252362,"name":"Karin Thursky","orcid":"0000-0002-7400-232X","position":6,"is_corresponding":false},{"id":229106,"name":"Simon J. Harrison","orcid":"0000-0003-4555-6582","position":7,"is_corresponding":false},{"id":252364,"name":"Monica A. Slavin","orcid":"0000-0002-8443-314X","position":8,"is_corresponding":false},{"id":1318719,"name":"Gemma Reynolds","orcid":"0000-0002-9561-3592","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort","abstract":"• CAR HEMATOTOX performed best a predictor of late, severe infections in an Australian cohort. • Post-infusion immunomodulatory therapies and neutropenia were associated with increased infection risk in multivariable models. The CAR-HEMATOTOX (HT) predicts prolonged neutropenia after CAR-T therapy. Aggressive lymphoma patients with HT scores ≥ 2 (HT high ) have experienced higher rates of severe infections compared to patients with lower scores (HT low ). 1 We aimed to validate HT’s prediction capability in an independent aggressive lymphoma cohort, treated with standard-of-care CAR-T, between January 2019 and September 2023. HT scores were calculated according to original methods. Infections were defined as microbiologically-confirmedor clinically-diagnosed. Severe infections were classified as CTCAE grade ≥ 3. Logistic regression evaluated HT’s association with infections within 90 days , and separately for early (Day 0-30) and late (D30-90) infections. Model fit was evaluated by AUC. Among 109 patients infections occurred in 31 patients (54% grade ≥ 3). HT high status was not associated with any-grade infections across D0-90 (OR = 1.91, 95%CI: 0.82-4.42, p = 0.13), but was significantly associated with severe infections (OR = 8.67, 95%CI: 2.30-32.68, p = 0.001), with very good discriminative validity (AUC = 0.74). HT high status performed as a better predictor for late severe infections (AUC = 0.85), compared with early severe infections (AUC = 0.62). Multivariable logistic regression also identified tocilizumab (OR = 1.52, 95%CI: 1.02 – 2.38, p = 0.041), prolonged neutropenia (OR = 11.95, 95%CI: 1.64 – 210.75, p = 0.001), and prolonged steroid (OR = 38.58, 95%CI: 2.05 – 725.91, p < 0.01) as significantly associated with infection. The relationship between HT high and risk of severe infection was validated in our L-BCL cohort. HT high was an excellent discriminative predictor of late severe infections.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4416185311","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.35980322,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.bict.2025.100020","host_type":"journal"},{"url":"https://doi.org/10.1016/j.bict.2025.100020","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S305059762500020X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S305059762500020X?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":["CAR-T cell therapy research","Immunotherapy and Immune Responses","Neutropenia and Cancer Infections"],"mesh_terms":[],"keywords":["Logistic regression","Neutropenia","Cohort","Severity of illness","Cohort study","Lymphoma"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T18:33:46.574896Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}